Trials / Unknown
UnknownNCT03961737
Study of the Response to Irradiation on Prostatic Explants ex Vivo, as a Predictive Factor of the Clinical Response to Irradiation of Prostate Cancers
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 92 (estimated)
- Sponsor
- Institut Cancerologie de l'Ouest · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Of the 50,000 prostate cancers that occur each year in France, more than half will benefit from curative radiotherapy, alone or in combination with hormone therapy from 6 months to 3 years depending on the stage of the disease. At present, there are few ways to predict the response to this irradiation. Evaluating the early response of tumor tissue to irradiation could predict the final response to treatment. It is difficult to offer biopsies during treatment for reasons of patient comfort. This is why this study consists in analysing transcriptomic and protein responses (immunohistochemistry) to irradiation on ex vivo prostate explants. These explants will be irradiated after culture and the transcriptional and immunohistochemical changes analysed before and after irradiation to determine an early tumor tissue response profile to irradiation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | prostate biopsies | Before radiotherapy treatment, prostate biopsies will be performed in each patient. From these biopsies, explants will be performed. Half of these explants will be irradiated ex vivo and the other half will not receive any prior treatment. Then the patient will receive radiotherapy. It will be reviewed 2 years after the end of radiotherapy. New prostate biopsies will be performed to evaluate the tumor response to radiotherapy and to characterize the immunohistochemical and transcriptomic profiles of non-responder patients. |
Timeline
- Start date
- 2019-04-02
- Primary completion
- 2023-06-01
- Completion
- 2023-06-01
- First posted
- 2019-05-23
- Last updated
- 2022-04-22
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03961737. Inclusion in this directory is not an endorsement.